Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.
Axi-Cel Efficacy in R/R Indolent Non-Hodgkin Lymphoma …
Dec 10, 2024 · Axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated durable responses and long-term survival in patients with relapsed or refractory indolent non-Hodgkin lymphoma (follicular lymphoma [FL] and marginal zone lymphoma [MZL]), according to 5-year results from the phase 2 ZUMA-5 trial presented at the 2024 ASH Annual Meeting. 1. Among all treated patients (n = 159), the median overall ...
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
IMforte Shows Benefits of Lurbinectedin/Atezolizumab in ES-SCLC
Oct 15, 2024 · Lurbinectedin (Zepzelca) plus the PD-L1 inhibitor atezolizumab (Tecentriq) led to positive topline results in the phase 3 IMforte study (NCT05091567) vs atezolizumab alone when used as maintenance therapy in extensive-stage small cell lung cancer (ES-SCLC). 1 The combination showed statistically significant improvements in overall survival (OS) and progression-free survival (PFS) as assessed ...
FDA Grants Priority Review to Durvalumab in MIBC
Dec 6, 2024 · Behind the Phase 3 NIAGARA Trial. NIAGARA is a randomized, open-label, multicenter, global trial which enrolled adult patients with cisplatin-eligible MIBC with a clinical stage of T2-T4aN0/1M0. 2 Patients were evaluated, confirmed for radical cystectomy, and had urothelial carcinoma with or without divergent differentiation or histologic subtypes. . Further, patients were required to have an ...
GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.
Teclistamab Maintenance Regimens Safe, Show Strong Initial …
Dec 9, 2024 · Teclistamab (Tec; Tecvayli) as a single agent or combined with standard lenalidomide (Len; Revlimid) was safe and demonstrated robust initial clinical activity as maintenance following induction and autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma, according to initial results from the safety run-in (SRI) component of the phase 3 MajesTEC-4/EMN30 ...
First Patients Dosed in New Phase 3 Trials of Dato-DXd in NSCLC
Nov 4, 2024 · The first patients have been dosed in 3 phase 3 trials evaluating various combinations of datapotamab deruxtecan (Dato-DXd) for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC). 1 TROPION-Lung10 (NCT06357533) is investigating Dato-DXd plus rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, or rilvegostomig alone vs pembrolizumab (Keytruda) in ...
November 2024 FDA Updates: Key Developments in Oncology
Dec 2, 2024 · During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Daratumumab Quadruplet Improves Outcomes in Transplant …
Dec 4, 2024 · The phase 3 CEPHEUS trial (NCT03652064) demonstrated that adding subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) to bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved treatment outcomes for patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for or deferred autologous stem cell transplant (ASCT). 1